Somewhat Positive News Coverage Somewhat Unlikely to Impact Ardelyx (ARDX) Share Price
Headlines about Ardelyx (NASDAQ:ARDX) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ardelyx earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.1967637879067 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Ardelyx (NASDAQ:ARDX) opened at $6.20 on Wednesday. The stock has a market cap of $297.09, a P/E ratio of -2.78 and a beta of 0.44. Ardelyx has a one year low of $4.05 and a one year high of $15.40.
Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.10. During the same quarter in the prior year, the firm earned ($0.65) earnings per share. equities analysts anticipate that Ardelyx will post -2.01 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Ardelyx (ARDX) Share Price” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/02/07/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-ardelyx-ardx-share-price.html.
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.